Loading...
28 diet COVID-19 controlled studies
https://c19early.org/dtmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Mahto 20% 0.80 [0.49-1.21] IgG+ 23/206 70/483 Improvement, RR [CI] Treatment Control Naushin 40% 0.60 [0.50-0.71] seropositive n/a n/a Kim 72% 0.28 [0.10-0.82] m/s case 41 (n) 527 (n) Kim 59% 0.41 [0.16-0.99] m/s case 46 (n) 522 (n) Kim 19% 0.81 [0.56-1.15] cases 41 (n) 527 (n) Kim 23% 0.77 [0.55-1.08] cases 46 (n) 522 (n) Merino 41% 0.59 [0.47-0.74] severe case 148,142 (n) 148,143 (n) Merino 18% 0.82 [0.78-0.86] cases 148,142 (n) 148,143 (n) Merino 9% 0.91 [0.88-0.94] cases 148,142 (n) 148,143 (n) Moludi 92% 0.08 [0.05-0.19] cases n/a n/a Ahmadi -3% 1.03 [0.77-1.39] death 185/206,286 62/75,264 Nguyen 15% 0.85 [0.75-0.96] symp. case 345/1,054 433/1,082 Yamamoto 66% 0.34 [0.13-0.85] cases 4/20 19/32 Magaña 53% 0.47 [0.22-0.99] death 58 (n) 31 (n) Jagielski 82% 0.18 [0.04-0.65] cases 4/40 9/20 Perez-Araluce 78% 0.22 [0.03-1.77] severe case 1/1,103 10/3,300 Perez-Araluce 15% 0.85 [0.62-1.15] symp. case 52/1,103 214/3,300 Perez-Araluce 20% 0.80 [0.60-1.07] cases 58/1,103 248/3,300 Firoozi 65% 0.35 [0.28-0.43] cases case control per unit E-DII change Hou 72% 0.28 [0.04-1.95] severe case 1/22 78/487 Hou 11% 0.89 [0.58-1.36] m/s case 11/22 273/487 Hou 74% 0.26 [0.10-0.67] severe case 0/9 47/127 Hou 35% 0.65 [0.43-0.99] m/s case 5/9 108/127 Zargarzadeh 77% 0.23 [0.11-0.50] severe case 89 (n) 80 (n) Yue 19% 0.81 [0.69-0.94] cases n/a n/a Yue 21% 0.79 [0.67-0.94] cases n/a n/a Yue 29% 0.71 [0.61-0.83] cases n/a n/a Yue 12% 0.88 [0.76-1.02] cases n/a n/a Zhou 16% 0.84 [0.78-0.91] cases 1,321/10,254 1,935/10,253 Ebrahimzadeh 69% 0.31 [0.14-0.68] severe case n/a n/a Ebrahimzadeh 56% 0.44 [0.18-1.06] hosp. n/a n/a Ebrahimzadeh 68% 0.32 [0.15-0.68] no recov. n/a n/a Tadbir Vajargah 67% 0.33 [0.16-0.69] severe case 83 (n) 83 (n) Tadbir Vajargah 72% 0.28 [0.14-0.58] severe case 83 (n) 83 (n) Tadbir Vajargah 75% 0.25 [0.12-0.53] severe case 83 (n) 83 (n) Reis 75% 0.25 [0.12-0.52] hosp. 17/380 21/166 Zhao 24% 0.76 [0.53-1.09] death 39,230 (n) 39,231 (n) Zhao 30% 0.70 [0.50-0.99] death 39,230 (n) 39,231 (n) Zhao 28% 0.72 [0.60-0.86] severe case 39,230 (n) 39,231 (n) Zhao 29% 0.71 [0.60-0.85] severe case 39,230 (n) 39,231 (n) Zhao 15% 0.85 [0.81-0.91] cases 39,230 (n) 39,231 (n) Zhao 9% 0.91 [0.85-0.96] cases 39,230 (n) 39,231 (n) Mohajeri 25% 0.75 [0.63-0.88] progression 62/105 392/495 Mohajeri 51% 0.49 [0.40-0.60] progression 50/105 482/495 Mohajeri 70% 0.30 [0.21-0.43] progression 23/105 365/495 Mohajeri -10% 1.10 [1.03-1.17] progression 98/105 421/495 Mohajeri 53% 0.47 [0.36-0.61] progression 38/105 380/495 Mohajeri 26% 0.74 [0.58-0.94] progression 44/105 280/495 Wang 9% 0.91 [0.72-1.14] PASC 124/318 218/480 LONG COVID Wang 49% 0.51 [0.33-0.78] PASC 188 (n) 66 (n) LONG COVID Zamanian 81% 0.19 [0.07-0.55] hosp. case control Barania Adabi 99% 0.01 [0.00-0.21] ICU 0/125 37/125 Barania Adabi 98% 0.02 [0.00-0.31] ICU 0/125 26/125 Aghajani 88% 0.12 [0.04-0.29] severe case case control Wang 45% 0.55 [0.29-1.03] severe case 81 (n) 67 (n) Wang 32% 0.68 [0.49-0.97] viral+ 81 (n) 67 (n) Micek 70% 0.30 [0.07-1.13] cases 32 (n) 21 (n) Pavlidou 55% 0.45 [0.41-0.51] cases 2,609 (n) 2,588 (n) Diet COVID-19 outcomes c19 earlyNovember 2023 Favors healthy diet Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of over 100,000 datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Vaccines and treatments are complementary. All practical, effective, and safe
means should be used based on risk/benefit analysis. No treatment, vaccine, or
intervention is 100% available and effective for all current and future
variants. We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
